Condition: Glioblastoma, IDH-wildtype · Metformin · Malignancies · Sponsor: University of Milano Bicocca
About 75% of CNS malignant tumors are classified as gliomas and the IDH-wildtype glioblastoma (GBM) represents the most aggressive form among CNS malignancies. This is a nationwide single-center phase II drug clinical trial with an approximate duration of 32 months. The clinical trial will be single-arm to evaluate the biological activity and effects of metformin in combination with TMZ in patients with GBM.
This description comes directly from the study's public registry record.
Manuela Caroli, Dott.ssa · 0255035502 · manuela.caroli@policlinico.mi.it
Rosa Maria Moresco, Dott.ssa · 0264488256 · rosa.moresco@unimib.it
Always discuss trial participation with your own doctor first.
| Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano | Milan, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05929495